Compare

Rapport Therapeutics, Inc. vs Rigel Pharmaceuticals Inc vs Ardelyx, Inc. vs Olema Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Rapport Therapeutics, Inc. RAPP	Rigel Pharmaceuticals Inc RIGLRevenue covers only part of its income (partial revenue)	Ardelyx, Inc. ARDX	Olema Pharmaceuticals, Inc. OLMA
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	$407.32M	n/a
Revenue growth (YoY)	n/a	n/a	+22.1%	n/a
Gross margin	n/a	n/a	90.3% (computed)	n/a
Operating margin	n/a	n/a	-10.1%	n/a
Net margin	n/a	n/a	-15.1%	n/a
Net income	-$111.48M	$367.02M	-$61.60M	-$162.45M
EPS (Diluted)	-$2.86	$19.48	-$0.26	-$1.87
Operating cash flow	-$87.47M	$75.66M	-$42.48M	-$146.72M
Free cash flow	-$88.09M	n/a	-$43.98M	n/a
Cash & equivalents	$52.65M	$40.58M	$68.00M	$48.30M
Total assets	$512.43M	$513.59M	$501.60M	$533.43M
Total liabilities	$27.78M	$122.11M	$334.65M	$54.87M
Shareholders' equity	$484.65M	$391.48M	$166.95M	$478.56M
Return on year-end equity	-23.0%	93.8%	-36.9%	-33.9%
Shares outstanding	47.77M	18.31M	244.35M	81.38M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Rapport Therapeutics, Inc.	Rigel Pharmaceuticals Inc	Ardelyx, Inc.	Olema Pharmaceuticals, Inc.
Latest	n/a	n/a	$407.32M Ended 2025-12-31	n/a
1 year earlier	n/a	n/a	$333.62M Ended 2024-12-31	n/a
2 years earlier	n/a	n/a	$124.46M Ended 2023-12-31	n/a
3 years earlier	n/a	n/a	$52.16M Ended 2022-12-31	n/a
4 years earlier	n/a	n/a	$10.10M Ended 2021-12-31	n/a